2022 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ & ACC(American College of Cardiology) Asia (¿Â,¿ÀÇÁ¶óÀÎ)(2ÀÏÂ÷) : 2022-04-16±³À°ÀÏÀÚ : 2022-04-16
±³À°Àå¼Ò : °æÁÖ HICO
±³À°ÁÖÁ¦ :
2022 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ & ACC(American College of Cardiology) Asia (¿Â,¿ÀÇÁ¶óÀÎ)(2ÀÏÂ÷) ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
´ã´çÀÚ : Á¶À±ÇÏ
¿¬¶ôó : 02-3275-5258
À̸ÞÀÏ :
herz8@circulation.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
°æ»óºÏµµ±³À°½Ã°£ : 8 ½Ã°£ 55ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í ±³¼ö ¹× °³¿øÀÇ: 80,000, ÀüÀÓÀÇ/Àü°øÀÇ/±âŸ: 40,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-16 Rm.102 08:00~08:12 How to Assess the Prognosis of TR Jun-Bean Park(Seoul National Univ. Korea)
±³À°½Ã°£ 04-16 Rm.102 08:12~08:24 Imaging of the TV, Echocardiography and More Jin Sun Park(Ajou Univ. Korea)
±³À°½Ã°£ 04-16 Rm.102 08:24~08:36 Overview of Percutaneous TV Devices Judy Hung(Massachusetts General Hospital USA)
Åä·Ð 04-16 Rm.102 08:36~08:45 Discussion ()
ÈÞ½Ä 04-16 08:45~08:55 ()
±³À°½Ã°£ 04-16 Rm.105 08:55~09:10 Overview of Non-Statin Therapies Laurence Sperling(Emory Univ.USA)
±³À°½Ã°£ 04-16 Rm.105 09:10~09:15 Case: Fibrates Jae Bin Seo(Seoul National Univ. Korea)
Åä·Ð 04-16 Rm.105 09:15~09:20 Discussion ()
±³À°½Ã°£ 04-16 Rm.105 09:20~09:25 Case: Fish oil, Icosapent Ethyl Hyun-Jin Kim(Hanyang Univ. Korea)
Åä·Ð 04-16 Rm.105 09:25~09:30 Discussion ()
±³À°½Ã°£ 04-16 Rm.105 09:30~09:35 Case: PCSK9 Inhibitors Youngwoo Jang(Gachon Univ. Korea)
Åä·Ð 04-16 Rm.105 09:35~09:40 Discussion ()
ÈÞ½Ä 04-16 09:40~09:50 ()
±³À°½Ã°£ 04-16 Rm.205 09:50~10:05 Obesity and Hypertension: Pathophysiologic Link ÀÌ»ó¿(°æÈñÀÇ´ë)
±³À°½Ã°£ 04-16 Rm.205 10:05~10:20 Management of Obesity: Beyond Life Style Modifications ±èº¸¿¬(¼øõÇâÀÇ´ë)
Åä·Ð 04-16 Rm.205 10:20~10:35 Discussion ()
ÈÞ½Ä 04-16 10:35~10:45 ()
±³À°½Ã°£ 04-16 Rm.205 10:45~10:57 Endurance Exercise: Mostly Good but a Few Concerns ÀÌÁ¾¿µ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 04-16 Rm.205 10:57~11:09 High‐Intensity Interval Training for Patients with Cardiovascular Disease—Is It Safe? Á¦¼¼¿µ(¼¿ï½Ã¸³´ë)
±³À°½Ã°£ 04-16 Rm.205 11:09~11:14 Endurance exercise (Rebuttal) ÀÌÁ¾¿µ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 04-16 Rm.205 11:14~11:19 High‐Intensity Interval Training (Rebuttal) Á¦¼¼¿µ(¼¿ï½Ã¸³´ë)
Åä·Ð 04-16 Rm.205 11:19~11:30 Discussion ()
ÈÞ½Ä 04-16 11:30~11:40 ()
±³À°½Ã°£ 04-16 Rm.102 11:40~11:55 Guideline-based Strategy in Lipid Optimization After ACS: When to Check? ±è¹Îö(Àü³²ÀÇ´ë)
±³À°½Ã°£ 04-16 Rm.102 11:55~12:10 Clinical Differentiation of Evolocumab in LDL-C Management ÀÌ¿øÀç(¼¿ïÀÇ´ë)
Åä·Ð 04-16 Rm.102 12:10~12:20 Discussion ()
ÈÞ½Ä 04-16 12:20~12:30 ()
±³À°½Ã°£ 04-16 Rm.300C 12:30~13:15 Interventional Therapy: What¡¯s Next Roxana Mehran(USA)
ÈÞ½Ä 04-16 13:15~13:20 ()
±³À°½Ã°£ 04-16 Rm.203 13:20~13:40 Monoclonal Antibody and Cardiotoxicty for Cardiologists º¯ÀÚ¹Î(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-16 Rm.203 13:40~14:00 CAR-T and Potential Cardiotoxicity for Cardiologists ¹Ú¼º¼ö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 04-16 Rm.203 14:00~14:20 Immune Check Point Inhibitor and Cardiotoxicity for Cardiologists ¹Ú¼¼ÈÆ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 04-16 Rm.203 14:20~14:40 Immnunotherapy Related Cardiotoxicity: Cardiologist ±èÀº°æ(¼º±Õ°üÀÇ´ë)
Åä·Ð 04-16 Rm.203 14:40~14:50 Discussion ()
ÈÞ½Ä 04-16 14:50~15:00 ()
±³À°½Ã°£ 04-16 Rm.105 15:00~15:10 Differential maneuvers for SVT ÁøÀº¼±(°æÈñÀÇ´ë)
±³À°½Ã°£ 04-16 Rm.105 15:10~15:20 How to ablate slow pathway without complications ±èµ¿Çõ(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 04-16 Rm.105 15:20~15:30 How to ablate difficult accessory pathways ±èÁø¼®(°í·ÁÀÇ´ë)
±³À°½Ã°£ 04-16 Rm.105 15:30~15:40 How to map complex atrial tachycardia ÀÓÈ«ÀÇ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 04-16 Rm.105 15:40~15:50 How to map and ablate fascicular ventricular tachycardia ¹ÚÁø±Ô(ÇѾçÀÇ´ë)
±³À°½Ã°£ 04-16 Rm.105 15:50~16:00 How to map and ablate RVOT PVC/VT ±èÁØ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 04-16 Rm.105 16:00~16:10 How to map and ablate LVOT PVC/VT ¹Ú°æ¹Î(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 04-16 Rm.105 16:10~16:20 How to reduce radiation exposure in EP lab ±èÁø¹è(°æÈñÀÇ´ë)
Åä·Ð 04-16 Rm.105 16:20~16:30 Discussion ()
ÈÞ½Ä 04-16 16:30~16:40 ()
±³À°½Ã°£ 04-16 Rm.103 16:40~16:52 Pro: CRT for HFrEF with Afib ±èÀÎö(°è¸íÀÇ´ë)
±³À°½Ã°£ 04-16 Rm.103 16:52~17:04 Con: CRT for HFrEF with Afib ¹Ú½ÂÁ¤(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 04-16 Rm.103 17:04~17:09 Pro Rebuttal ±èÀÎö(°è¸íÀÇ´ë)
±³À°½Ã°£ 04-16 Rm.103 17:09~17:14 Con Rebuttal ¹Ú½ÂÁ¤(¼º±Õ°üÀÇ´ë)
Åä·Ð 04-16 Rm.103 17:14~17:25 Discussion ()
±³À°½Ã°£ 04-16 Rm.103 17:25~17:37 Pro: Stem cell therapy for HF °ÁöÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-16 Rm.103 17:37~17:49 Con: Stem cell therapy for HF Á¶À翵(Àü³²ÀÇ´ë)
±³À°½Ã°£ 04-16 Rm.103 17:49~17:54 Pro Rebuttal °ÁöÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-16 Rm.103 17:54~17:59 Con Rebuttal Á¶À翵(Àü³²ÀÇ´ë)
Åä·Ð 04-16 Rm.103 17:59~18:10 Discussion ()